S

SugenTech Inc
KOSDAQ:253840

Watchlist Manager
SugenTech Inc
KOSDAQ:253840
Watchlist
Price: 6 210 KRW -2.2% Market Closed
Market Cap: ₩104B

Net Margin

-230.9%
Current
Declining
by 26.9%
vs 3-y average of -204%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-230.9%
=
Net Income
₩-20.8B
/
Revenue
₩9B

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-230.9%
=
Net Income
₩-20.8B
/
Revenue
₩9B

Peer Comparison

Country Company Market Cap Net
Margin
KR
SugenTech Inc
KOSDAQ:253840
94.9B KRW
Loading...
US
Abbott Laboratories
NYSE:ABT
189.6B USD
Loading...
US
Intuitive Surgical Inc
NASDAQ:ISRG
171B USD
Loading...
US
Stryker Corp
NYSE:SYK
138.8B USD
Loading...
IE
Medtronic PLC
NYSE:MDT
132.5B USD
Loading...
US
Boston Scientific Corp
NYSE:BSX
115.7B USD
Loading...
US
Becton Dickinson and Co
NYSE:BDX
58.8B USD
Loading...
DE
Siemens Healthineers AG
XETRA:SHL
46.4B EUR
Loading...
US
IDEXX Laboratories Inc
NASDAQ:IDXX
51.8B USD
Loading...
US
Edwards Lifesciences Corp
NYSE:EW
45.4B USD
Loading...
US
Resmed Inc
NYSE:RMD
39B USD
Loading...

Market Distribution

Lower than 96% of companies in Korea
Percentile
4th
Based on 2 632 companies
4th percentile
-230.9%
Low
-168 471.3% — -2.9%
Typical Range
-2.9% — 5.8%
High
5.8% — 21 012.5%
Distribution Statistics
Korea
Min -168 471.3%
30th Percentile -2.9%
Median 1.9%
70th Percentile 5.8%
Max 21 012.5%

SugenTech Inc
Glance View

Market Cap
104B KRW
Industry
Health Care

Sugentech, Inc. develops in-vitro diagnostic systems and products. The company is headquartered in Daejeon, Daejeon. The company went IPO on 2016-11-11. The firm is involved in the manufacturing and sale of in vitro diagnostic test reagents, point-of-care testing (POCT) products, folic acid products under the name of SOLGAR, as well as molecular diagnostic reagents. The in vitro diagnostic test reagents are for personal use and are sold under the name SUREARLY. The POCT products are for professional use and are sold under the name INCLIX. In addition, the Company is engaged in therapeutic drug monitoring, as well as drug analysis method development. The firm distributes its products within the domestic market and to overseas markets, including Indonesia.

Intrinsic Value
2 718.05 KRW
Overvaluation 56%
Intrinsic Value
Price
S
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-230.9%
=
Net Income
₩-20.8B
/
Revenue
₩9B
What is SugenTech Inc's current Net Margin?

The current Net Margin for SugenTech Inc is -230.9%, which is below its 3-year median of -204%.

How has Net Margin changed over time?

Over the last 3 years, SugenTech Inc’s Net Margin has decreased from 50.1% to -230.9%. During this period, it reached a low of -523.3% on Sep 30, 2023 and a high of 50.1% on Aug 30, 2022.

Back to Top